

## APPOINTMENT OF CHIEF FINANCIAL OFFICER

Resonance Health Ltd (ASX: RHT) (**Resonance** or **Company**) advises that Mr Benjamin Carruthers has been appointed as Chief Financial Officer (**CFO**) and is expected to commence the role in October 2023.

Mr Carruthers is a seasoned professional with over 20 years' experience in advisory, restructuring and turnaround in listed and private entities across a range of industries including mining and resources, services, retail, manufacturing, aquaculture and marine, education and training, and franchising.

He brings extensive experience in M&A transactions, due diligence, modelling, and financial management. He holds a Bachelor of Commerce (Accounting & Finance), Bachelor of Arts (French) and is a Chartered Accountant.

His most recent role was as General Manager at SFM Marine, and prior to that he was an Executive Director at Korda Mentha.

Andrew Harrison, Chief Executive Officer of Resonance said this of the appointment:

*"Benjamin brings a wealth of experience to Resonance as we embark on our strategy of growth and profitability. His transaction experience along with a strong financial focus and discipline will make a pivotal contribution to the senior executive team and further underpin the Company's growth".*

### Key Terms of CFO's Agreement

The key terms of Mr Carruthers employment arrangements are as follows:

- Fixed remuneration of \$225,000 per annum plus statutory superannuation.
- Short-term incentive of up to 20% of fixed remuneration based on the achievement of KPIs aligned with shareholder interests, or payable in the event of a change of control.
- Eligible to participate in the Long-term Incentive Scheme, to be agreed and issued under the Company's ESOP.
- Employment may be terminated by the Company or Mr Carruthers on 3 months' notice.

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd. For further information please contact:

**Andrew Harrison – Chief Executive Officer**

E: [andrewh@resonancehealth.com](mailto:andrewh@resonancehealth.com)

P: +61 (0)8 9286 5300

## About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2\***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2\*. CardiacT2\* is TGA and CE Marking regulatory cleared.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at [www.resonancehealth.com](http://www.resonancehealth.com) and to follow Resonance Health on Facebook, LinkedIn, and Twitter.

### FOLLOW US



/Resonance-Health-Ltd



/ResonanceHealth



/ResonanceHealthLtd